Education
About Us
Working with TipRanks
Follow Us
Cutia Therapeutics (HK:2487)
:2487
2487 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$3.64 - HK$18.26
Previous CloseN/A
Volume1.53M
Average Volume (3M)1.92M
Market Cap
HK$3.01B
Enterprise ValueHK$2.71B
Total Cash (Recent Filing)HK$876.15M
Total Debt (Recent Filing)¥320.94M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding320,359,100
10 Day Avg. Volume1,329,030
30 Day Avg. Volume1,919,076
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)2.88
Price to Sales (P/S)0.00
P/FCF Ratio-10.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cutia Therapeutics News
PremiumCompany Announcements
Cutia Therapeutics Gains Approval for Innovative Hair Loss Treatment in China
PremiumCompany Announcements
Cutia Therapeutics Successfully Passes All Resolutions at AGM
PremiumCompany Announcements
Cutia Therapeutics Schedules Annual General Meeting with Key Resolutions
PremiumCompany Announcements
Cutia Therapeutics Schedules Board Meeting to Approve Annual Results
PremiumCompany Announcements
Cutia Therapeutics Completes Promising Phase II Trials
PremiumCompany Announcements
Cutia Therapeutics Reports Promising Trial Results2487 FAQ
What was Cutia Therapeutics’s price range in the past 12 months?
Cutia Therapeutics lowest stock price was HK$3.64 and its highest was HK$18.26 in the past 12 months.
What is Cutia Therapeutics’s market cap?
Cutia Therapeutics’s market cap is HK$3.01B.
When is Cutia Therapeutics’s upcoming earnings report date?
Cutia Therapeutics’s upcoming earnings report date is Aug 27, 2025 which is in 56 days.
How were Cutia Therapeutics’s earnings last quarter?
Cutia Therapeutics released its earnings results on Mar 24, 2025. The company reported -HK$0.778 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.778.
Is Cutia Therapeutics overvalued?
According to Wall Street analysts Cutia Therapeutics’s price is currently Overvalued.
Does Cutia Therapeutics pay dividends?
Cutia Therapeutics does not currently pay dividends.
What is Cutia Therapeutics’s EPS estimate?
Cutia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cutia Therapeutics have?
Cutia Therapeutics has 320,359,100 shares outstanding.
What happened to Cutia Therapeutics’s price movement after its last earnings report?
Cutia Therapeutics reported an EPS of -HK$0.778 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.695%.
Which hedge fund is a major shareholder of Cutia Therapeutics?
Currently, no hedge funds are holding shares in HK:2487
Cutia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.61%
12-Months-Change
Fundamentals
Return on Equity
-37.29%
Trailing 12-Months
Asset Growth
-21.10%
Trailing 12-Months
Company Description
Cutia Therapeutics
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.
Technical Analysis
Jacobio Pharmaceuticals Group Co., Ltd.
―
Viva Biotech Holdings
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
CStone Pharmaceuticals
―
SinoMab Bioscience Ltd.
―